Vor Biopharma Inc complete an upsized $176.9 million IPO, offering 9.83 million shares at $18 each.
The stock opened at $42.02 was jumped 104.9% in early action.
Our top pick for
Beginners
Our top pick for
Free trades
Our top pick for
Active traders
| Latest market close | $4.02 |
|---|---|
| 52-week range | $3.83 - $18.52 |
| 50-day moving average | $4.96 |
| 200-day moving average | $6.77 |
| Wall St. target price | $21.13 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-2.10 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $4.02 from 2022-09-26
| 1 week (2022-09-21) | -11.65% |
|---|---|
| 1 month (2022-08-26) | -17.79% |
| 3 months (2022-06-28) | -27.83% |
| 6 months (2022-03-28) | -36.89% |
| 1 year (2021-09-28) | -74.21% |
|---|---|
| 2 years (2020-09-24) | N/A |
| 3 years (2019-09-24) | N/A |
| 5 years (2017-09-24) | N/A |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -20.39% |
| Return on equity TTM | -38.21% |
| Profit margin | 0% |
| Book value | $4.67 |
| Market capitalisation | $165.9 million |
TTM: trailing 12 months
We're not expecting Vor Biopharma to pay a dividend over the next 12 months.
Vor Biopharma, Inc. , a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases.
Everything we know about the YanGuFang International Group IPO, plus information on how to buy in.
Looking to invest in tech? Here’s how to buy shares in the major tech companies, known as FAANG stocks.
A simple guide to buying stocks in your favorite European soccer team.
Steps to owning and managing JUVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing ASR, with 24-hour and historical pricing before you buy.
Steps to owning and managing BVB, with 24-hour and historical pricing before you buy.
Everything we know about the Lead Real Estate Co. IPO, plus information on how to buy in.
Everything we know about the Third Harmonic Bio IPO, plus information on how to buy in.
Everything we know about the LINKBANCORP IPO, plus information on how to buy in.
Here are the stocks that benefit from inflation, as well as industries to keep an eye on to reduce the impacts of inflation on your portfolio.